|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-5-23
|
|
pubmed:abstractText |
Survival following metastatic or recurrent Ewing sarcoma family tumors (ESFT) remains <25%. Myeloablative therapy with hematopoietic stem cell transplantation (HSCT) may improve survival for poor-risk ESFT. We describe the toxicity and efficacy of a myeloablative chemotherapy regimen, followed by a second myeloablative radiotherapy regimen as consolidation treatment for poor-risk ESFT.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0098-1532
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
328-37
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10797354-Adolescent,
pubmed-meshheading:10797354-Adult,
pubmed-meshheading:10797354-Antineoplastic Agents, Alkylating,
pubmed-meshheading:10797354-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10797354-Bone Marrow,
pubmed-meshheading:10797354-Bone Marrow Purging,
pubmed-meshheading:10797354-Busulfan,
pubmed-meshheading:10797354-Cause of Death,
pubmed-meshheading:10797354-Child,
pubmed-meshheading:10797354-Child, Preschool,
pubmed-meshheading:10797354-Disease Progression,
pubmed-meshheading:10797354-Disease-Free Survival,
pubmed-meshheading:10797354-Feasibility Studies,
pubmed-meshheading:10797354-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10797354-Humans,
pubmed-meshheading:10797354-Melphalan,
pubmed-meshheading:10797354-Neoplasm Recurrence, Local,
pubmed-meshheading:10797354-Prognosis,
pubmed-meshheading:10797354-Remission Induction,
pubmed-meshheading:10797354-Sarcoma, Ewing,
pubmed-meshheading:10797354-Survival Rate,
pubmed-meshheading:10797354-Thiotepa,
pubmed-meshheading:10797354-Treatment Outcome,
pubmed-meshheading:10797354-Treatment Refusal
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
|
|
pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Seattle, WA, USA. dhawki@chmc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
